Gastrointestinal Drugs Advisory Committee
Committee Meeting on July 21, 2011, from 8 a.m. to 4 p.m.
Agenda: On July 21, 2011, the committee will discuss the results from a clinical trial of supplement biologics license application 103772/5301, REMICADE (infliximab), by Centocor Ortho Biotech Inc., in the treatment of pediatric patients with moderately to severely active ulcerative colitis.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment